AI is increasingly being integrated across various industries, demonstrating its versatility and potential. In the biotech sector, it is important to consider how the use of AI might impact integral factors such as GCP compliance and inspection readiness. The incorporation of AI in the clinical trial process brings about a transformative influence on GCP compliance and inspection readiness. Through automation, AI can streamline routine tasks and data analysis by improving accuracy and decreasing the risk of human error. With that being said, there are prominent obstacles to consider when looking to incorporate AI into the drug development process.
Discover insights on this topic from Ernesto Vera Sanchez, Vice President and Head of GxP Strategy, in our recent podcast. Dr. Sanchez discusses how to leverage AI technology, while being proactive in your compliance strategy and ensuring your trial is well-prepared for success.
Start listening to this podcast by clicking play button below
Ernesto Vera-Sanchez
Vice President, Division Head GxP Strategy
If you’re interested in hearing about transformative potential of ADCs and RDCs and the critical steps required to achieve regulatory approval, please listen to another exciting Allucent podcast: Advancing Oncology Research: Regulatory & Development Path for ADCs & RDCs with experts Sugato De, VP of Regulatory Strategy and Head of Med Tech, and Alex MacDonald, Vice President of model-informed drug development (MIDD)
Share This
